On October 19, 2026 PharmaMar (MSE: PHM), leader in the research, development, and commercialization of marine-derived oncology therapies reported it will participate in the European Society Medical Oncology (ESMO) (Free ESMO Whitepaper), taking place in Madrid from October 23rd to 27th.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Company will present two posters on PM54, one on the preliminary results of this molecule in advanced solid tumors and the other on CombiVista, an AI tool that identifies and prioritizes oncology drug combinations across multiple workstreams for further development.
PharmaMar will also host a Satellite Symposium on Saturday, October 24th between 18:30 – 20:00h focused on the latest advances in the treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The symposium, chaired by Professor Silvia Novello from Oncology Department AOU San Luigi, University of Turin, Italy and with the participation of Professor Martin Reck, Head of the Department of Thoracic Oncology at the Lung Clinic Grosshansdorf, Germany, Professor Raffaele Califano, Consultant in Medical Oncology at The Christie and University Hospital of South Manchester, United Kingdom and Dr. Luis Paz-Ares, Head of Medical Oncology Department at Hospital Universitario 12 de Octubre, Madrid, Spain.
Luye, PharmaMar’s partner in China, will present the results of an exploratory study of flat-dose lurbinectedin plus serplulimab as first-line maintenance therapy in Chinese Patients with ES-SCLC.
The Association for Research on Lung Cancer in Women (ICAPEM), In collaboration with PharmaMar, will present two posters on the CLARISSE study, the first project in Spain to analyze the evolution of SCLC over the past six years, in more than 4,400 patients across the country. The posters will cover both the trends in sex-based differences and sex and clinical trial participation in SCLC.
Highlighted studies at ESMO (Free ESMO Whitepaper) 2026
PRODUCT TITLE AUTHOR ABSTRACT
PM54 CombiVista: An Evidence-Driven Decision Support Tool for Prioritizing Oncology Drug Combinations Across Multiple Workstreams I. Carmi-Levy TYPE: e-Poster SESSION: AI for Clinical research and drug development ABSTRACT: 164eP
Safety and Preliminary Activity of PM54 in Two Phase I Clinical Studies with Different Treatment Schedules M. de Miguel SESSION: Developmental therapeutics ABSTRACT: 1054P DATE: Fri, 23.10.2026 Time 15:15 – 16:00
Zepzelca (lurbinectedin) Flat-Dose Lurbinectedin Plus Serplulimab as First-Line Maintenance Therapy in Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: An Exploratory Study L. Chong TYPE: Poster SESSION: SCLC ABSTRACT: 3818P DATE: Mon, 26.10.2026 Time 12:00 – 12:45
SCLC Time Trends in Sex-Based Differences in SCLC: CLARISSE Study J. Chamorro-Pérez TYPE: e-Poster SESSION: SCLC ABSTRACT: 3863Ep
Sex and Clinical Trial Participation in Small Cell Lung Cancer: the CLARISSE study Y. Lague TYPE: Poster SESSION: SCLC ABSTRACT: 3830P DATE: Mon, 26.10.2026 Time 12:00 – 12:45
Trabectedin Quantitative PARP1 H-score as a predictive biomarker for trabectedin plus olaparib combination in advanced soft tissue sarcoma: exploratory analysis of the TOMAS2 study L. D’Ambrosio TYPE: rapid oral session SESSION: Sarcoma DATE: Mon, 26.10.2026 08:30 – 10:00 Malaga Auditorium – Hall 3
(Press release, PharmaMar, OCT 19, 2026, View Source [SID1234673562])